NASDAQ:PRFX PainReform (PRFX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free PRFX Stock Alerts $0.88 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.81▼$0.8850-Day Range$0.81▼$2.3152-Week Range$0.69▼$26.41Volume39,106 shsAverage Volume120,769 shsMarket Capitalization$1.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get PainReform alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About PainReform Stock (NASDAQ:PRFX)PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Read More PRFX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRFX Stock News HeadlinesApril 18, 2024 | globenewswire.comPainReform Announces Closing of $4 Million Public OfferingApril 16, 2024 | finance.yahoo.comPainReform Announces Pricing of $4 Million Public OfferingApril 23, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 9, 2024 | msn.comEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsApril 9, 2024 | finance.yahoo.comPainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | globenewswire.comPainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 4, 2024 | finance.yahoo.comUK watchdog says Theramex-Viatris deal raises competition concernsApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management MarketApril 23, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 2, 2024 | finance.yahoo.comEXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain DrugApril 2, 2024 | globenewswire.comPainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyMarch 7, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid CrisisMarch 1, 2024 | globenewswire.comPainReform Provides Year-End Business UpdateJanuary 22, 2024 | finance.yahoo.comPainReform to Present at the Microcap Conference in Atlantic CityJanuary 12, 2024 | msn.comPainReform files to sell 968,545 ordinary shares for holdersJanuary 5, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market AdvantageJanuary 3, 2024 | finance.yahoo.comPainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefDecember 26, 2023 | finance.yahoo.comPainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsDecember 19, 2023 | benzinga.comPainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and DatesNovember 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)November 15, 2023 | finance.yahoo.comPainReform Provides Business Update for the Third Quarter of 2023November 12, 2023 | morningstar.comPainReform Ltd Ordinary Shares PRFXSeptember 12, 2023 | markets.businessinsider.comPainReform (PRFX) Gets a Buy from Maxim GroupSeptember 11, 2023 | finance.yahoo.comPainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySee More Headlines Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/22/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRFX CUSIPN/A CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.65 per share Price / Book0.18Miscellaneous Outstanding Shares2,030,000Free Float1,329,000Market Cap$1.73 million OptionableNot Optionable Beta0.53 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ehud Geller Ph.D.Executive ChairmanMr. Ilan Hadar M.B.A. (Age 55)CEO & CFO Comp: $404kDr. Sigal Aviel (Age 60)Chief Operating Officer Comp: $345kProf. Eli Hazum Ph.D.CTO & DirectorMs. Rita Keynan (Age 55)Vice President of Pharmaceutical Operations Comp: $302kDr. Stephen A. Cooper D.M.D Ph.D.Executive Vice President of DevelopmentMore ExecutivesKey CompetitorsNeuBase TherapeuticsNASDAQ:NBSE180 Life SciencesNASDAQ:ATNFBaudax BioNASDAQ:BXRXGRI BioNASDAQ:GRIBiodexa PharmaceuticalsNASDAQ:BDRXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 170,000 shares on 2/13/2024Ownership: 10.897%View All Institutional Transactions PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed in 2024? PainReform's stock was trading at $2.75 on January 1st, 2024. Since then, PRFX shares have decreased by 68.0% and is now trading at $0.8789. View the best growth stocks for 2024 here. When is PainReform's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PRFX earnings forecast. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($1.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.30) by $2.50. When did PainReform's stock split? PainReform's stock reverse split on the morning of Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU). When did PainReform IPO? PainReform (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRFX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
